Berlex Fellowship Open

Exploring New Possibilities in Kidney Cancer Detection and Therapy

The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Overcoming Physical and Social Barriers in the Lymphoma Field

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Ozuriftamab Vedotin Gains FDA Fast Track Designation for Recurrent SCCHN

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Roman Fabbricatore

SON-080 May Decrease Chemotherapy-Induced Peripheral Neuropathy

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Related Content

Ariana Pelosci

Exploring New Possibilities in Kidney Cancer Detection and Therapy

The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Overcoming Physical and Social Barriers in the Lymphoma Field

The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Ozuriftamab Vedotin Gains FDA Fast Track Designation for Recurrent SCCHN

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Roman Fabbricatore